Literature DB >> 26363495

Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.

D Caudal1, A Alvarsson2, A Björklund3, P Svenningsson4.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of nigral dopaminergic neurons and by the presence of aggregates containing α-synuclein called Lewy bodies. Viral vector-induced overexpression of α-synuclein in dopaminergic neurons represents a model of PD which recapitulates disease progression better than commonly used neurotoxin models. Previous studies using this model have reported motor and cognitive impairments, whereas depression, mood and anxiety phenotypes are less described. To investigate these psychiatric phenotypes, Sprague-Dawley rats received bilateral injections of a recombinant adeno-associated virus (AAV) vector expressing human α-synuclein or GFP into the substantia nigra pars compacta. Behavior was assessed at two timepoints: 3 and 8 weeks post-injection. We report that nigral α-synuclein overexpression led to a pronounced nigral dopaminergic cell loss accompanied by a smaller cell loss in the ventral tegmental area, and to a decreased striatal density of dopaminergic fibers. The AAV-α-synuclein group exhibited modest, but significant motor impairments 8 weeks after vector administration. The AAV-α-synuclein group displayed depressive-like behavior in the forced swim test after 3 weeks, and reduced sucrose preference at week 8. At both timepoints, overexpression of α-synuclein was linked to a hyperactive hypothalamic-pituitary-adrenal (HPA) axis regulation of corticosterone. The depressive-like phenotype was also correlated with decreased nigral brain-derived neurotrophic factor and spinophilin levels, and with decreased striatal levels of the activity-regulated cytoskeleton-associated protein. This study demonstrates that AAV-mediated α-synuclein overexpression in dopamine neurons is not only useful to model motor impairments of PD, but also depression. This study also provides evidence that depression in experimental Parkinsonism is correlated to dysregulation of the HPA axis and to alterations in proteins involved in synaptic plasticity.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alpha-synuclein; Anxiety; Corticosterone; Depression; Parkinson disease

Mesh:

Substances:

Year:  2015        PMID: 26363495     DOI: 10.1016/j.expneurol.2015.09.002

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  20 in total

Review 1.  How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?

Authors:  Laura A Volpicelli-Daley; Deniz Kirik; Lindsay E Stoyka; David G Standaert; Ashley S Harms
Journal:  J Neurochem       Date:  2016-05-04       Impact factor: 5.372

2.  Individual Amino Acid Supplementation Can Improve Energy Metabolism and Decrease ROS Production in Neuronal Cells Overexpressing Alpha-Synuclein.

Authors:  Vedad Delic; Jeddidiah W D Griffin; Sandra Zivkovic; Yumeng Zhang; Tam-Anh Phan; Henry Gong; Dale Chaput; Christian Reynes; Vinh B Dinh; Josean Cruz; Eni Cvitkovic; Devon Placides; Ernide Frederic; Hamed Mirzaei; Stanley M Stevens; Umesh Jinwal; Daniel C Lee; Patrick C Bradshaw
Journal:  Neuromolecular Med       Date:  2017-06-15       Impact factor: 3.843

3.  Parvalbumin-containing GABA cells and schizophrenia: experimental model based on targeted gene delivery through adeno-associated viruses.

Authors:  Marta U Woloszynowska-Fraser; Peer Wulff; Gernot Riedel
Journal:  Behav Pharmacol       Date:  2017-12       Impact factor: 2.293

4.  In utero delivery of rAAV2/9 induces neuronal expression of the transgene in the brain: towards new models of Parkinson's disease.

Authors:  L Chansel-Debordeaux; M Bourdenx; S Dovero; V Grouthier; N Dutheil; A Espana; L Groc; C Jimenez; E Bezard; B Dehay
Journal:  Gene Ther       Date:  2017-11-16       Impact factor: 5.250

5.  PET imaging of the influence of physiological and pathological α-synuclein on dopaminergic and serotonergic neurotransmission in mouse models.

Authors:  Elise Levigoureux; Caroline Bouillot; Thierry Baron; Luc Zimmer; Sophie Lancelot
Journal:  CNS Neurosci Ther       Date:  2018-05-20       Impact factor: 5.243

Review 6.  New Developments in Genetic rat models of Parkinson's Disease.

Authors:  Rose B Creed; Matthew S Goldberg
Journal:  Mov Disord       Date:  2018-02-08       Impact factor: 10.338

7.  Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology.

Authors:  Fredric P Manfredsson; Kelvin C Luk; Matthew J Benskey; Aysegul Gezer; Joanna Garcia; Nathan C Kuhn; Ivette M Sandoval; Joseph R Patterson; Alana O'Mara; Reid Yonkers; Jeffrey H Kordower
Journal:  Neurobiol Dis       Date:  2018-01-16       Impact factor: 5.996

Review 8.  Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease: clues to early diagnosis and effective treatment.

Authors:  Yeojin Bang; Juhee Lim; Hyun Jin Choi
Journal:  Arch Pharm Res       Date:  2021-06-19       Impact factor: 4.946

Review 9.  Adeno-Associated Virus Expression of α-Synuclein as a Tool to Model Parkinson's Disease: Current Understanding and Knowledge Gaps.

Authors:  Taylor E Huntington; Rahul Srinivasan
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

Review 10.  What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?

Authors:  R Magnard; Y Vachez; C Carcenac; P Krack; O David; M Savasta; S Boulet; S Carnicella
Journal:  Transl Psychiatry       Date:  2016-03-08       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.